Huntington Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Huntington
Disease Market Outlook
Thelansis’s “Huntington Disease
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2025 To 2035” covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Huntington
Disease treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Huntington
Disease Overview
Huntington’s
disease (HD) is a devastating, fully penetrant, autosomal dominant
neurodegenerative disorder fundamentally driven by a deleterious CAG
trinucleotide repeat expansion within the HTT gene, yielding a
toxic, aggregation-prone mutant huntingtin (mHTT) protein. Clinically
characterized by genetic anticipation—whereby successive generations frequently
experience earlier disease onset and heightened severity—the core pathology is
hallmarked by the profound, progressive atrophy of the striatum (specifically
the caudate nucleus and putamen) and widespread cerebral cortical thinning. The
distinct evolution of motor symptoms is directly dictated by the sequential
vulnerability of striatal medium spiny neurons (MSNs); the early, selective
destruction of enkephalin-expressing MSNs in the indirect pathway drives the
pathognomonic hyperkinetic chorea, whereas the subsequent loss of
substance-P-expressing MSNs in the direct pathway precipitates progressive
rigidity, dystonia, and akinesia. Beyond movement abnormalities, patients
present with a highly morbid clinical triad that includes devastating cognitive
decline (subcortical dementia) and severe, often prodromal psychiatric
disturbances, notably major depression, profound apathy, and impulsivity.
Because no disease-modifying therapies currently exist to halt or reverse this
fatal neurodegenerative cascade, the modern therapeutic paradigm remains
strictly palliative. Clinical management relies entirely on a rigorous
multidisciplinary approach, aggressively integrating targeted psychiatric
pharmacotherapy with vesicular monoamine transporter 2 (VMAT2) inhibitors—such
as tetrabenazine or deutetrabenazine—to definitively suppress severe chorea and
maximize the patient’s functional quality of life throughout the irreversible
disease trajectory.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and
China)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g., drug uptake and erosion)
datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across G8
markets (US, EU5, Japan, and China)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment